Perfecting The European Medtech Accelerator And Funding Vehicle

Sofinnova Partners’ early-stage, "stay lean" approach to funding and incubating innovative medtech is unique in Europe, believes partner Anne Osdoit. She is seeking more investments for the company’s major MD Start III fund, while trying not to focus too much on thoughts of the next iteration.

Alamy
• Source: Alamy

Venture capital firm Sofinnova Partners has a track record of investing in innovative health care and life science technologies across many different “strategies,” which are its platforms for various candidate companies at their different stages of development.

Medtech accounts for some 25% of Sofinnova’s capital funds strategy, which invests in seed, series A and B yields. Medtech...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from In Vivo